Accelerating Cell & Gene Therapies: Collaboration With NecstGen

bioMérieux and NecstGen, a centre of excellence for Cell and Gene Therapies (CGT), have partnered to accelerate the development of CGT through the provision of ‘state of the art’ quality and safety testing technologies that will allow safe and effective advanced therapeutics production.

Thanks to this new partnership, CGT researchers and manufacturers, hosted at NecstGen, will benefit from bioMérieux's solutions and services to monitor and test their products and processes. bioMérieux rapid methods for Sterility testing, Mycoplasma detection and Endotoxin testing will help break down testing bottlenecks, further optimizing CGT development and improving access to these much-needed treatments for patients.

bioMérieux sat down with experts from NecstGen to discuss the value of this partnership, the impact of rapid quality control, and the future of CGT.

Part 1️⃣ | Melissa and Josep share their perspective on current constraints and challenges in CGT quality control, and what criteria they look for when choosing new solutions.

Part 2️⃣ | Melissa and Josep discuss why collaboration across analytical development, quality control, and manufacturing is extremely important in ensuring cell and gene therapy products are safe for patients.

Part 3️⃣ | Melissa and Josep speak to the value our solutions and services bring to their organization as they help CGT developers deliver a new generation of treatment to patients.

Part 4️⃣ | Melissa and Josep dive into what they think the future of cell and gene therapies holds, as well as their ambitions for NecstGen over the next few years.